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Abstract: Vaccination has been well recognised as a critically important tool in preventing infectious
disease, yet incomplete immunisation coverage remains a major obstacle to achieving disease control
and eradication. As medical products for global access, vaccines need to be safe, effective and
inexpensive. In line with these goals, continuous improvements of vaccine delivery strategies are
necessary to achieve the full potential of immunisation. Novel technologies related to vaccine delivery
and route of administration, use of advanced adjuvants and controlled antigen release (single-dose
immunisation) approaches are expected to contribute to improved coverage and patient compliance.
This review discusses the application of micro- and nano-technologies in the alternative routes of
vaccine administration (mucosal and cutaneous vaccination), oral vaccine delivery as well as vaccine
encapsulation with the aim of controlled antigen release for single-dose vaccination.
Keywords: vaccine delivery; compliance; microfluidics; mucosal vaccination; cutaneous
vaccination; adjuvants
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1. Introduction
Estimated global immunisation coverage varies per country and per vaccine, with some vaccines
such as pneumococcal and rotavirus ranging between 35–47%, falling significantly short of the WHO’s
recommended coverage of >90%. Although many different factors affect these figures, vaccination
compliance is one of the major obstacles to broader immunisation coverage globally. Pain that is felt
during parenteral vaccine administration is one of the most frequently reported causes of vaccine
hesitancy. Success of the oral polio vaccine in bringing the disease close to eradication (notwithstanding
recent issues related to the vaccine itself [1]), and the increasing uptake of the nasal flu vaccine for
children, indicate that non-injectable routes of vaccination have a significant impact on improving
coverage and compliance. Vaccines also have a critical role in slowing down and preventing the
spread of antibiotic resistance worldwide [2]. Approaches to broaden vaccination coverage include the
development of new technologies for the mode and route of vaccine administration, and formulations
for cutaneous, oral and mucosal delivery (Figure 1). We discuss here the targeted strategies and key
innovations of different vaccination technologies, highlighting their potential to overcome common
vaccination-related limitations and improve compliance.
Vaccines 2020, 8, x 2 of 29 
1. Introduction 
Estimated global immunisation coverage varies per country and per vaccine, with some vaccines 
such as pneumococcal and rotavirus ranging between 35–47%, falling significantly short of the 
WHO’s recommended coverage of >90%. Although many different factors affect these figures, 
vaccination compliance is one of the major obstacles to broader immunisation coverage globally. Pain 
that is felt during parenteral vaccine administration is one of the most frequently reported causes of 
vaccine hesitancy. Success of the oral polio vaccine in bringing the disease close to eradication 
(notwithstanding recent issues related to the vaccine itself [1]), and the increasing uptake of the nasal 
flu vaccine for children, indicate that non-injectable routes of vaccination have a significant impact 
on improving coverage and compliance. Vaccines also have a critical role in slowing down and 
preventing the spread of antibiotic resistance worldwide [2]. Approaches to broaden vaccination 
coverage include the development of new technologies for the mode and route of vaccine 
administration, and formulations for cutaneous, oral and mucosal delivery (Figure 1). We discuss 
here the targeted strategies and key innovations of different vaccination technologies, highlighting 
their potential to overcome common vaccination-related limitations and improve compliance. 
 
Figure 1. Advanced vaccination technologies and strategies for improving compliance and coverage. 
Key drug delivery systems to overcome barriers associated with each administration route are 
presented: (a) nasal and pulmonary immunisation using particulate delivery systems such as lipid-
based systems (liposomes or nanocapsules), polymeric nanoparticles (NPs), gold NPs, self-assembled 
NPs (e.g., chitosan), dendrimers, and micelles; (b) oral immunisation using delivery systems such as 
hydrogels, scaffolds, and particles (nano- and microparticles); (c) cutaneous immunisation can be 
performed using microneedles, scaffolds, hydrogels, nano- and microparticles; (d) advanced 
technologies for improving vaccine manufacture and delivery, such as single-dose immunisation 
using polymeric NPs, and vaccine encapsulation using emulsions or microfluidics systems. Figure 
prepared using BioRender. 
  
Figure 1. Advanced vaccination technologies and strategies for improving compliance and coverage.
Key drug delivery systems to overcome barriers associated with each administration route are
presented: (a) nasal and pulmonary immunisation using particulate delivery systems such as lipid-based
systems (liposomes or nanocapsules), polymeric nanoparticles (NPs), gold NPs, self-assembled
NPs (e.g., chitosan), dendrimers, and micelles; (b) oral immunisation using delivery systems such
as hydrogels, scaffolds, and particles (nano- and microparticles); (c) cutaneous immunisation can
be performed using microneedles, scaffolds, hydrogels, nano- and microparticles; (d) advanced
technologies for improving vaccine manufacture and delivery, such as single-dose immunisation using
polymeric NPs, and vaccine encapsulation using emulsions or microfluidics systems. Figure prepared
using BioRender.
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2. Vaccine Formulations for Pulmonary and Nasal Delivery
Mucosal immunity is the first and foremost line of defence against pathogens that enter the
body through the oral mucosa and the nasal cavity, such as influenza and viruses causing meningitis,
measles or whooping cough. Estimates of the surface area of the mucus membranes lining the
lungs vary between 50–75 square meters, representing the largest epithelial surface exposed to the
outside environment. However, most licensed vaccines are administered by intramuscular injection,
which preferentially induces systemic immune responses [3]. Protective mucosal responses can be
effectively elicited by mucosal immunisation [4]; furthermore, mucosal vaccines are attractive by being
non-invasive and needle-free.
The airway mucosa is the site of substantial immunological activity where constant immune
monitoring recruits highly professional innate and adaptive immune cells, to protect the host from
microbial and environmental insults. Nasopharynx-associated lymphoid tissue (NALT) is an organised
mucosal immune system that consists of lymphoid tissue, B cells, T cells and antigen presenting cells
(APCs), covered by an epithelial layer containing microfold (M) cells [5]. M cells in the epithelial cell
layers have a specialised role in transporting antigens across the epithelium [5,6]. Following mucosal
administration, immunity is induced at mucosal as well as serosal surfaces and in both local and distal
mucosa. Compared to conventional injectable vaccines, mucosal vaccines have many other advantages:
ease of administration, better patient compliance, lower costs, avoidance of needle stick injuries and
needle waste, and the scope for mass immunisation [7]. The interconnection of various mucosal sites
through a common mucosal immune system allows the possibility to immunise via the nose against
infectious diseases that originate from distal mucosal sites [8].
Intranasal administration of a vaccine allows the induction of a strong systemic and local immune
response. In a recent phase I clinical trial of a novel intranasal respiratory syncytial virus (RSV) F
protein vaccine, which was linked to an immunostimulatory bacterium-like particle, persistent nasal
IgA and serum IgG responses were observed for up to six months [9]. In addition, the enzymatic
activity in the nasal cavity is relatively weak, compared to the oral route, which can be a reason why
some vaccines are more efficient when administered intranasally. In a study that compared the mucosal
delivery of the intranasal and oral Bordetella bronchiseptica vaccine, the intranasal vaccine conferred
stronger clinical immunity [10]. However, antigens can also be rapidly removed from the nasal cavity
or poorly absorbed by epithelial cells, potentially leading to reduced immunogenicity [11]. Nasal
vaccines can be delivered in the form of powder, aerosol, gel or drops. Each of these forms have their
advantages and disadvantages, as reviewed previously [12].
Mucosal vaccination can protect against several mucosally transmitted bacterial and viral diseases,
and a few oral and nasal mucosal vaccines have been authorised for use in humans e.g., sabin
polio, rotavirus, and nasal influenza vaccine [7]. All of these mucosal vaccines are based on the entire
pathogen, either killed or live attenuated. Thus, they are associated with many disadvantages including
laborious and expensive production and distribution, and the risk of reversion to the virulent form.
Conversely, the new generation of subunit vaccines that are based on single or multiple highly
purified pathogenic antigens, such as peptides, proteins, polysaccharides, and nucleic acids, represent
safer alternatives. Such subunit vaccines are inherently poorly immunogenic and require the
inclusion of an adjuvant. This is especially relevant for mucosal delivery routes where the targeted
mucosal epithelium, which naturally is in contact with many possible antigens, requires a strong
immune-potentiating signal in order not to induce tolerance [13]. Subunit vaccines for pulmonary
and nasal immunisation, when combined with adjuvants, can overcome many of the shortcomings
of conventional vaccines. Table 1 summarises the vaccines delivered through pulmonary and nasal
routes in different phases of clinical testing.
Adjuvants comprise structurally diverse compounds, which can be categorised as delivery systems
or immunopotentiators, or a combination of both [14]. Delivery systems enhance the immune response
against the co-delivered antigen by protecting it from degradation and allowing sustained antigen
release. Different classes of delivery systems that can be used as a platform technology for delivering
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vaccines include liposomes, polymer particles, inorganic particles, bacterial or viral vectors, outer
membrane vesicles, immunostimulating complexes, emulsions, and virus-like particles (Table 2).
These vaccine carriers can extend the residence time of the antigen on the mucosa, which increases
its chances of getting into the deeper layers and reaching the immune cells [15]. Different strategies
can be used to deliver vaccine antigen to the mucosa: mucoadhesion, M cell targeting or targeting
APCs. Mucoadhesion can be achieved by employing positively charged carriers such as chitosan
or liposomes.
Endocine™ is a mucosal adjuvant based on endogenous lipids found in the human body that
possess a negative charge. It was shown to be both safe and effective in inducing a humoral and
cell-mediated immune (CMI) response after intranasal administration in animal models, including
in aged mice [16]. A positively charged oil-in-water nanoemulsion, when combined with the H5
hemagglutinin antigen, was recently shown to be effective in protecting against influenza challenge
in ferrets [17]. A carrier composed of liposomes covered with chitosan induced both systemic and
mucosal immunity in mice when administered intranasally together with an epitope from group A
Streptococcus protein [18]. There are many specific targets on the M cell surface that can be used for
designing an efficient vaccine carrier [19]. Khan et al. used a conjugate of GB-1 M cell ligand and F and
G protein fragments from RSV to vaccinate mice intranasally and reported an efficient mucosal and
systemic response, as well as protection against nasal challenge with RSV [20]. The conjugation of
chitosan with mannose increases its engulfment by dendritic cells (DCs) and macrophages, as these cells
express the mannose receptor on their surface. Mannosylated chitosan used in a DNA vaccine against
M. tuberculosis administered intranasally to mice-induced secretory IgA (sIgA) in the broncho-alveolar
lavage (BAL) fluid and provided improved protection in challenge experiments [21]. Another example
is the use ofβ-glucan which is recognised by the Dectin-1 receptor localised on DCs [22]. The addition of
β-glucan to chitosan-HbsAg vaccine significantly increased the anti-HbsAg antibody titre in immunised
mice [23]. It has to be underlined that in some cases the exact mechanism of APC targeting is unknown.
DOTAP/DC-chol liposomes administered intranasally with pneumococcal surface protein A provided
protection against pneumococcal infection, and were shown to be specifically engulfed by DCs,
even though these particles do not possess any known DC ligands [24].
Immunopotentiators activate the immune system through pattern-recognition receptors (PRRs)
expressed by APCs. Immunopotentiators can be bacterial or viral toll-like receptor (TLR) agonists,
stimulator of interferon genes (STING) agonists, and cytokines (Table 3). Delivery systems and
immunopotentiators together determine the magnitude and quality of the innate immune response
and the subsequent adaptive immune response specific to the co-delivered vaccine antigen. Vaccine
antigens are delivered to dendritic cells, the most specialised APCs, initiating the differentiation of
T-helper cell subsets, which in turn interact with B cells, eventually resulting in the production of
antibodies (sIgA) at mucosal sites [8].
Dry Powders for Pulmonary Immunisation
Most vaccine antigens are macromolecules, such as polysaccharides, proteins, peptides, and nucleic
acids, and usually are at a great risk of chemical and physical degradation in liquid formulations [25].
All vaccines lose potency over time, and the rate of potency loss is dependent on the handling
and storage temperature. The delivery of vaccine antigens in the form of dry powder particles
to the lungs is recognised as a potential immunisation strategy that improves vaccine stability in
comparison to liquid vaccine formulations [26]. The thermostability of vaccine antigens can be
further improved by formulating them as dry powder microparticles in the presence of sugars
as stabilising excipients [26]. A number of drying methods such as spray-drying, freeze-drying,
and spray freeze-drying are used to prepare dry powder vaccine particles [26]. These approaches
to develop thermostable vaccine formulations that are resistant to damage caused by freezing or
overheating also eliminate the dependence on a cold chain. Thus, dry powder-based inhalable
vaccine formulations for pulmonary immunisation not only induce systemic and mucosal immune
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responses [8], but also have logistical advantages over injectable vaccines [26]. Dry powder-based
vaccine formulations have been designed and pre-clinically tested against several infectious diseases,
progressing into clinical trials (Table 1). An inhalable vaccine formulation of alginate-coated live
Mycobacterium microparticles was more immunogenic than liquid aerosols, and provided better
protection in mice against experimental Mycobacterium tuberculosis infection [27]. In another study,
an intrapulmonary-delivered Advax-adjuvanted influenza vaccine induced higher memory B and
T cell responses than intranasal or intramuscular immunisation and conferred superior disease
protection [28]. The development of inhalable dry powder vaccines is thus a promising new strategy
for pulmonary immunisation. However, a number of parameters defines the optimal performance of
dry powder vaccines such as aerodynamic particle size, aerosolisation performance, antigen stability,
controlled release, drug delivery device, safety, and the scale-up of manufacturing. Advancements in
pharmaceutical and nano-technologies enabling the development and testing of dry powder vaccines
for pulmonary immunisation should help to lay the groundwork for the successful commercialisation
of the first aerosolised mucosal vaccine.
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Table 1. Pulmonary and nasally delivered vaccines in clinical trials.
Study Title Pathogen/Condition Vaccine
Administration
Route Status Phase
Clinical Trials Gov
Identifier
Intrapulmonary
Phase 1 Clinical Trial of the Safety and Immunogenicity of an
Adenovirus-Based TB Vaccine Administered by Aerosol Tuberculosis Ad5Ag85A Pulmonary Recruiting I NCT02337270
Investigating Immune Responses to Aerosol Bacillus
Calmette–Guérin (BCG) Challenge in Healthy UK Adults Tuberculosis BCG Danish Pulmonary Recruiting I NCT03912207
ChAdOx1 85A Aerosol Versus Intramuscular Vaccination in
Healthy Adults (TB039) (TB039) Tuberculosis ChadOx1 85A Pulmonary Recruiting I NCT04121494
Nasal
Evaluating the Safety and Immune Response to a Single Dose of
a respiratory syncytial virus (RSV) Vaccine in Infants and
Children
RSV infection RSV ∆NS2 ∆1313I1314L Nasal Recruiting I NCT01893554
Safety and Immunogenicity of a RSV Vaccine in RSV-Seropositive
Children and RSV-Seronegative Infants and Children RSV infection D46cp∆M2-2 vaccine Nasal
Active, not
recruiting I NCT02601612
Evaluating the Infectivity, Safety, and Immunogenicity of the
Recombinant Live-Attenuated RSV Vaccines in
RSV-Seronegative Infants 6 to 24 Months of Age
RSV infection
RSV
∆NS2/∆1313/I1314L
and RSV 276
Nasal Active, notrecruiting I NCT03227029
Evaluating the Infectivity, Safety, and Immunogenicity of a RSV
Vaccine in RSV-Seropositive Children and RSV-Seronegative
Infants and Children
RSV infection RSV 6120/∆NS2/1030s Nasal Recruiting I NCT03387137
Evaluating the Infectivity, Safety, and Immunogenicity of the
Recombinant Live-Attenuated RSV Vaccines in
RSV-Seronegative Infants and Children 6 to 24 Months of Age
RSV infection
RSV
∆NS2/∆1313/I1314L
and RSV 276
Nasal Active, notrecruiting I NCT03422237
A Study Assessing Colonisation and Immunogenicity after Nasal
Inoculation with N. lactamica and Eradication on Day 4 or 14 Meningitis Neisseria lactamica Nasal Recruiting
Not
applicable NCT03549325
Evaluating the Infectivity, Safety and Immunogenicity of RSV
Vaccines in RSV-Seropositive Children and RSV-Seronegative
Infants and Children
RSV infection
RSV 6120/∆NS1 and
RSV
6120/F1/G2/∆NS1
Nasal Recruiting I NCT03596801
Vaccines 2020, 8, 304 7 of 28
Table 1. Cont.
Study Title Pathogen/Condition Vaccine
Administration
Route Status Phase
Clinical Trials Gov
Identifier
Mucosal and Systemic Immunity after Viral Challenge of
Healthy Volunteers Vaccinated with Inactivated Influenza
Vaccine via the Intranasal Versus Intramuscular Route
Influenza Flucelvax: Inactivatedinfluenza vaccine Nasal Recruiting II NCT03845231
Safety and Immunogenicity of a Single Dose of the Recombinant
Live-Attenuated RSV Vaccines or placebo, delivered as nose
drops to RSV-Seronegative Children 6 to 24 Months of Age
RSV infection
RSV
∆NS2/∆1313/I1314L,
RSV 6120/∆NS2/1030s,
and RSV 276
Nasal Recruiting I/II NCT03916185
Nasal and Systemic Immune Responses to Nasal Influenza
Vaccine (Flu-M3) Influenza
Live attenuated
influenza vaccine Nasal
Active, not
recruiting
Not
applicable NCT04110366
A Controlled Study to Assess Safety, Colonisation and
Immunogenicity of Reconstituted Lyophilised Neisseria
lactamica (Lac5-Nasal)
Meningitis Lyophilised Neisserialactamica Nasal Recruiting
Not
applicable NCT04135053
A Safety and Immunogenicity of Intranasal Nanoemulsion
Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults
(IN NE-rPA)
Anthrax
BW-1010: a
nanoemulsion
adjuvanted
recombinant protein
Nasal Recruiting I NCT04148118
Live-Attenuated Influenza Vaccine as a Nasal Model for
Influenza Infection Influenza
Flumist quadrivalent
nasal vaccine Nasal
Not yet
recruiting IV NCT04164212
HSP, heat shock protein.
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Table 2. Delivery systems for pulmonary and nasally delivered vaccines.
Delivery System Pathogen/Antigen Administration Animal Model Immunity TypeGenerated Reference
Liposomes Mycobacterium tuberculosis (Mtb) H56antigen Pulmonary Mice Th1; Th17; IgA; IgG [29]
ISCOMs Human T cell lymphotropic virustype 1 Nasal Mice Th1; IgA; IgG [30]
Chitosan Dengue virus Nasal Mice CD8+ T cells; IgA; IgG [31]
γ-polyglutamic acid Group A Streptococcus Nasal Mice IgA; IgG [32]
Hyaluronic acid Influenza hemagglutinin Nasal Mice, Rabbits, Micro-pigs IgA; IgG [33]
Pullulan Streptococcus pneumoniae Nasal Macaques Th2; Th17; IgA; IgG [34]
Synthetic polymer-based
particles
PLGA Chlamydia trachomatis Nasal Mice Th1; IgA; IgG [35]
PEI H9N2 Influenza Nasal Mice Th1; CD8
+ T cells; IgA;
IgG [36]
PCL Hepatitis B Nasal Mice IgA; IgG [37]
PPS Mtb Nasal Mice Th1; Th17 [38]
Inorganic particles
Gold particles H3N2 hemagglutinin Nasal Mice Th1; CD8
+ T cells; IgA;
IgG [39]
Aluminium particles Ovalbumin Nasal Rats IgA; IgG [40]
Calcium phosphate particles Chimeric dengue virus serotype 2 Nasal Mice IgA [41]
Silica-based particles Foot and mouth disease virus Nasal Guinea pigs IgA; IgG [42]
Carbon nanoparticles Ovalbumin Nasal Mice Th1; CD8+ T cells [43]
Infectious materials
Recombinant bacteria Lactobacillus plantarum vector forMtb Nasal Mice Th1; IgA [44]
Recombinant virus Influenza virus vector for respiratorysyncytial virus Pulmonary; Nasal Mice CD8
+ T cells [45]
Outer membrane vesicles
(OMV)
Bacteroides thetaiotaomicron OMV
for Yersinia pestis V and F antigen Nasal Mice IgA; IgG [46]
Emulsions Helicobacter pylori Nasal Mice Th1; IgA; IgG [47]
VLPs Influenza VLPs Nasal Mice Th1; IgA; IgG [48]
HSP, heat shock protein; Ig, immunoglobulin; ISCOMs, immunostimulatory complexes; PCL, poly ε-caprolactone; PEI, polyethyleneimine; PLGA, poly (lactic-co-glycolic acid);
PPS, polyphenylene sulphide; Th, helper T cells; VLPs, virus-like particles.
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Table 3. Immunopotentiators for pulmonary and nasally delivered vaccines.
Immunopotentiator Pathogen/Antigen Administration Animal Model Immunity TypeGenerated Reference
Bacterial TLR agonists
Lipopeptides: TLR-1/2 agonists Mycobacterium tuberculosis Nasal Mice Th1; Th17 [49]
Lipopolysaccharide: TLR-4
agonist
Human T cell lymphotropic virus
type 1 Nasal Mice Th1; IgA; IgG [30]
Peptidoglycan: TLR-2/4
agonists Respiratory syncytial virus Nasal Mice Th1; Th2 [50]
Flagellin: TLR-5 agonist Influenza A virus Nasal Mice Th1; CD8
+ T cells; IgA;
IgG [51]
CpG DNA: TLR-9 agonist Foot and mouth disease virus Nasal Guinea pig IgA; IgG [42]
Viral TLR agonists
Double stranded RNA: TLR 3
agonist
Human parainfluenza virus type 3
virus Nasal Mice; Cotton rats; Pigs Th1; IgA [52]
Guanosine analogues: TLR-7/8
agonists Entamoeba histolytica Nasal Mice Th1; Th17; IgA; IgG [53]
STING agonist: Cyclic
dinucleotide GMP–AMP H1N1, H3N2, H5N1, H7N9 Influenza Nasal Mice; Ferrets
Th1; CD8+ T cells; IgA;
IgG [54]
Cytokines
Type I Interferons (IFN) Influenza Nasal Mice IgA; IgG [55]
IFN-γ Yersinia pestis Nasal Mice IgA; IgG [56]
GM-CSF HIV-1 Nasal Mice IgA; IgG [57]
IL-12 HIV Nasal Mice Th1; CD8
+ T cells; IgA;
IgG [58]
IL-15 Simian immunodeficiency virus Pulmonary Mice Th1; CD8+ T cells; ADCC [59]
IL-18 HIV Nasal Mice Th1; CD8+ T cells [60]
FLT-3 ligand Chlamydia abortus Nasal Mice Th1; IgA; IgG [61]
ADCC, antibody-dependent cell-mediated cytotoxicity; CpG, cytidine-phosphateguanosine; FLT-3, Fms-Like tyrosine kinase 3; GM-CSF, granulocyte-macrophage colony-stimulating factor;
GMP-AMP, guanosine monophosphate–adenosine monophosphate; HIV, human immunodeficiency virus; HN, hemagglutinin and neuraminidase; IL, interleukin; STING, stimulator of
interferon genes; TLR, toll-like receptor.
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3. Oral (Gastrointestinal) Vaccines
Oral delivery is the most patient-friendly route of administration, and consequently, oral vaccines
have the potential to improve vaccine efficacy by enhancing their accessibility and distribution, which
may lead to better vaccine coverage [3]. Oral vaccination is also regarded as the optimal means to fight
infections caused by enteric pathogens as it induces intestinal immunity through the gut-associated
mucosal tissues [62]. The first successfully implemented oral vaccine was the oral polio vaccine
developed in the 1950s by Albert Sabin. It had the ability to induce protective sIgA responses in the
intestinal mucosa, the main site of poliovirus entry and multiplication. This significantly reduced viral
transmission, leading towards the global eradication of polio [8]. Other licensed oral vaccines target
diseases induced by enteric pathogens such as Vibrio cholerae, Salmonella typhi and rotavirus, causing
cholera, typhoid fever and gastroenteritis, respectively [63].
Despite the clear benefits of oral vaccines, only a few have been successfully developed.
Oral vaccines have to overcome difficult challenges linked to the gastrointestinal biology: the
acidic environment in the stomach, the proteolytic enzymes necessary for protein degradation,
the presence of mucus, low intestinal permeability and the generally poor immunogenicity of orally
delivered antigens [64]. Consequently, an efficient oral vaccine should ideally be (1) stable in a highly
enzymatic environment and resistant to site-specific pH; (2) delivered to specific immune-induction
sites (e.g., Peyer’s patches in the small intestine); (3) adapted to interactions with mucus; (4) able to
be transported through the intestinal epithelial barrier; (5) captured by appropriate APCs and able
to evade mucosal tolerance [19]. A number of oral drug delivery technologies are currently under
pre-clinical and clinical development to overcome these challenges [65]. Various particle-, liposomal-
or adenoviral-based systems have been evaluated as vehicles to deliver the vaccine antigens [62]. Other
promising formulations are site-specific delivery systems, which are often capsule- or tablet-based.
These systems can facilitate antigen protection and the delivery of vaccines to specific areas of the
gastrointestinal tract and particularly to the key sampling sites such as the Peyer’s patches [19].
Site-specific release can be achieved through the application of pH-dependent coating such as shellac,
cellulose acetate phthalate, cellulose acetate trimellitate, poly(vinyl acetate phthalate), or hydroxypropyl
methylcellulose phthalate [66]. These delivery systems play an important role in the stability and the
delivery efficacy of vaccine components to the intestine. However, additional targeted strategies to
specifically induce intestinal immune responses may be beneficial.
Ligand-mediated vaccine delivery systems have been shown to direct antigens to specific receptors
expressed on intestinal M cells, epithelial cells or intestinal APCs [19]. Given the pivotal role of M
cells in antigen sampling, several lectin-, antibody- and peptide-based targeted strategies have been
developed to specifically engage these cells. Plant lectin-based ligands, facilitating the bioadhesion to
glycans expressed on M cells, have been tested. Ulex europaeus agglutinin-1 (UEA-1) was shown to
specifically bind to α-L-fucose residues expressed on mouse Peyer’s patch M cells [67,68] and able to
target polystyrene microparticles [69] or liposomes [70] to them. Since many intestinal pathogens gain
entry to the host through M cells, some M cell receptors used by bacteria have also been evaluated.
For example, glycoprotein 2 (GP2) is expressed on murine and human intestinal M cells, and Escherichia
coli (E. coli) and Salmonella enterica typhimurium are able to bind GP2 through FimH, a pili component on
the bacterial outer membrane [71]. The conjugation of an anti-GP2 monoclonal antibody to ovalbumin
(OVA) resulted in effective M cell targeting and oral immunisation with this system triggering enhanced
faecal OVA-specific sIgA responses compared to the antigen alone in mice [72]. Other M cell-specific
antibodies have been analysed. The conjugation of the anti-M cell antibody 5B11 to polystyrene
particles enhanced their uptake by rabbit intestinal M cells in an ileal loop model [73], while oral
vaccination with a conjugate of the NKM 16-2-4 antibody to botulinum toxoid (BT) enhanced BT-specific
serum IgG and mucosal IgA responses as well as protective immunity against lethal challenge with BT
in mice [74]. Finally, some peptides targeting M cells have been tested by oral route. The tripeptide
Arginine-Glycine-Aspartic Acid (RGD) motif, which could bind to β-integrins on M cells, was shown
to enhance antigen-specific serum IgG responses in mice [75] and the tetragalloyl-D-lysine dendrimer
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(TGDK) targeting murine, human, and nonhuman primate M cells was demonstrated to enhance faecal
antigen-specific IgA responses in macaques [76].
In addition to targeted strategies to engage specific cells, including M cells, the choice of antigen
and adjuvant is pivotal in developing efficient oral vaccines. The current licensed oral vaccines are
composed of either live-attenuated or killed organisms, sometimes in combination with protein subunit
components [77]. To enhance the antigen immunogenicity, novel recombinant enterotoxigenic E. coli
(ETEC) [78] and Vibrio cholerae [79] strains, overexpressing antigens or expressing multiple antigens,
have been developed and were successfully tested in animal models and in clinical trials. Considering
that much vaccine development is currently focused on subunit vaccines, the addition of adjuvants
to the formulation may be crucial to overcome intestinal tolerance. However, there are currently no
licensed adjuvanted oral vaccines for human use.
Cholera toxin (CT) and the heat-labile enterotoxin of E. coli (LT) have been shown to be potent
mucosal adjuvants in pre-clinical studies. However, the native forms of these toxins are too toxic for use
in humans, leading some research groups to develop toxin or toxin subunit mutants [77]. For instance,
double-mutant labile toxin (dmLT) has been tested in pre-clinical studies [80] and evaluated in a
Phase I clinical trial as part of a prototype oral ETEC vaccine [81]. Interestingly, dmLT was shown to
promote Th17 responses but also protective sIgA responses in pre-clinical studies [82]. A non-toxic CT
derivative was also developed as CTA1-DD which is a fusion between the A subunit of CT and the
D-fragment of the Staphylococcus aureus protein A [83]. CTA1-DD was shown to be safe and enhanced
the immunogenicity of various antigens in animal models [84].
Unconventional T cells such as invariant natural killer T (iNKT) cells or mucosal-associated
invariant T (MAIT) cells have been considered as potential adjuvant targets: Intestinal sites are
enriched in these cells which are at the interface between innate and adaptive immunity and can
modulate APCs [85]. Some iNKT cell agonists have been investigated as adjuvants to enhance immune
responses in immunotherapy and vaccination strategies [86]. Lavelle and colleagues demonstrated the
potential of the iNKT cell activator α-Galactosylceramide (α-GalCer) as an oral adjuvant to enhance
intestinal immune responses induced by experimental whole-cell killed ETEC [87], Vibrio cholerae [88]
and Helicobacter pylori [89] antigens in mouse models. In addition, a novel oral delivery-integrated
system named Single Multiple Pill® (SmPill®), containing oil-in-water emulsions formulated as
1 mm minispheres, was reported to effectively protect and enhance the release of various drugs
in targeted intestinal regions [90]. The SmPill® integrated system, incorporating a recombinant
formalin-killed whole-cell E. coli overexpressing the colonisation factor antigen I (CFA/I) and the
orally active adjuvant α-GalCer, was shown to facilitate a controlled and sustained antigen release
at intestinal pH [87]. Furthermore, this vaccine delivery system was able to enhance the intestinal
CFA/I-specific sIgA responses in mice. It was also shown that a novel whole-cell killed Vibrio cholerae
strain and recombinant cholera toxin subunit B (CTB) could be successfully loaded as antigens in
SmPill® minispheres. Consistent with the previous findings, Davitt and colleagues demonstrated that
combining these antigens and α-GalCer in SmPill® minispheres enhanced intestinal lipopolysaccharide
and CTB-specific IgA responses and induced intestinal antigen-specific Th1 responses (Figure 2) [88].
Finally, a key concern in vaccine formulation is stability. Indeed, the development of thermostable
vaccine formulations may improve vaccine coverage, especially in low-income countries. The stability
of this integrated oral delivery system containing formalin-killed whole-cell E. coli overexpressing
CFA/I, and the orally active adjuvant α-GalCer, was evaluated under various temperature and
humidity conditions. Longet and colleagues determined that SmPill® minispheres maintained both
the antigenicity of CFA/I and the immunostimulatory activity of the α-GalCer adjuvant after the
storage of SmPill® minispheres under room temperature and extreme storage conditions for several
months [91]. Collectively, these results support the potential of the SmPill® minisphere approach to
enhance the immunogenicity of orally delivered antigens [87] and maintain the stability of oral vaccine
formulations [91]. This exemplifies the potential to use integrated strategies to overcome challenges in
developing oral vaccines.
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Figure 2. Proposed mechanism of the SmPill® minispheres and the induction of intestinal
vaccine-specific immune responses: 1. The enteric coating of SmPill® minispheres remains intact in the
acidic environment of the stomach protecting the payload; 2. On exiting the stomach and the passage
into the increasing pH of the small intestine, the enteric coating begins to degrade, exposing the gelatine
core and releasing the oil droplets containing the vaccine antigen (e.g., whole-cell killed bacteria) and
the solubilised adjuvant (e.g., α-GalCer); 3. The payload is gradually released in the small intestine and
the antigen/adjuvant can cross the intestinal epithelium (e.g., through M cells) where the presentation
of processed whole-cell killed bacteria and α-GalCer by DCs to T cells and invariant natural killer T
(iNKT) cells occurs, respectively. This leads to B cell activation; 4. B cells undergo affinity maturation,
class switch recombination and differentiation into plasma cells, which enter into the circulation and
home back to the lamina propria where antigen-specific IgA secretion occurs; 5. Upon infection with
viable bacteria, sIgA transported into the intestinal lumen can neutralise the bacteria. Figure prepared
using BioRend r.
4. Cutaneous Immunisation
Skin or (trans)cutaneous vaccination is a route of immunisation mediated by topical, intradermal
(ID) or intraepidermal delivery [92]. In line with global aspirations to expand vaccination coverage,
cutaneous vaccines are regarded as a promising option for overcoming diverse issues, from vaccine
safety and reactogenicity to patient preferences [93]. As an immunocompetent and multi-functional
organ, the skin appears to be highly susceptible to certain vaccine adjuvants, resulting in enhanced
immunogenicity and allowing the reduction in antigen dose and immunisation frequency [94].
Therefore, it is important that the immunogenicity profiles of cutaneous vaccines are not significantly
inferior to other routes of vaccination [93]. Among the many technological approaches for cutaneous
vaccination, several deserve a more detailed overview.
Electroporation is an electro-permeabilisation method, being intensively explored in different
fields: DNA manipulation in vitro, drug delivery and gene therapy. It is based on the transitory
structural perturbation of lipid membranes (such as the cell membrane) through the application of
high-voltage electri al imp l es. Typically, electroporation involves the short-term exposure (few µs to
ms to high-voltage pulses (50–1500 V) with up to 1 s interv ls. It is hy othesised that a structural
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rearrangement in the lipid bilayer occurs, consequently forming transient pores and facilitating
molecular transport for both small molecules and biologics [95]. In the context of skin vaccine delivery,
the CELLECTRA® electroporation device (developed by Inovio Pharmaceuticals) has shown good
safety and efficacy [96] and is currently being assessed in a Phase III clinical study for DNA-based
immunotherapy of cervical cancer (NCT03721978). It has more recently also been applied to a
DNA-based coronavirus vaccine (NCT04336410). Interestingly, there are findings suggesting that
electroporation alone may act as a physical adjuvant, by stimulating the ‘trickling’ of Langerhans
cells (LCs) away from the treatment site (presumably to lymph nodes) and inducing a certain level of
pro-inflammatory cytokines [97].
Among the different thermal microporation technologies, fractional infrared laser ablation stands
out as particularly suitable for bypassing the skin barrier properties. It enables the disruption of
the stratum corneum in a highly controlled and adjustable fashion, simultaneously providing an
intrinsic adjuvanting effect. Consequently, this technology has been intensively investigated for the
pain-free prophylactic and therapeutic treatment of type I allergies and tumours [92,98,99]. Despite
a two-step administration process (microporation followed by antigen application), laser ablation
could potentially be valuable in mass vaccination campaigns, particularly in combination with dry
vaccine patches, offering advantages such as heat stability, the avoidance of needle-related injuries,
and improved uptake, at a cost similar to conventional vaccination [99]. Currently, the major challenge
is how to standardise the pore depth and ensure sufficient reproducibility, due to the variability of
skin thickness depending on body site, age and ethnicity [92]. The available results encourage further
investigations in healthy adults to evaluate the safety and efficacy of laser microporation prior to,
for example, vaccine patch application [98].
Microneedle arrays represent another interesting approach for intradermal vaccine delivery.
Although these devices comprise needles, their length (10–2000 µm) offers relatively pain-free
application [100]. Among the many microneedle types, future widespread vaccine delivery is
expected for solid and dissolvable needles [93,101]. However, attaining reproducible coating and
mechanical properties remain among the frequently noted critical attributes. Preclinical studies
conducted to date imply that microneedles may generate immunogenicity comparable to intradermal
or intramuscular vaccination, with some studies reporting higher and more durable antibody and
cellular responses [101]. Satisfactory immune responses may be attained even without adjuvant
addition or with considerably lower adjuvant doses than otherwise required, which is an important
safety asset [92]. Therefore, microneedle patches are relatively cost effective, easy to produce and
accepted well by the patients [102]. The fact that they allow self-administration may be the most
significant factor in the further prospects for this mode of vaccine delivery [101].
In the search for an improved needle-free vaccination strategy, the application of dry vaccine
powders using ballistic (powder) injectors seems to be a promising approach for delivering antigens to
the skin, owing to improved vaccine stability and cold-chain independent logistics [103,104]. As a result,
this technology has been recognised as potentially suitable for mass vaccination campaigns in
developing countries [104]. Numerous studies show that DNA and RNA vaccines, as well as
conventional vaccines in a dry state could be administered using the powder injectors [92]. However,
in order to achieve the successful delivery of a particulate vaccine into the skin, apart from the design
of ballistic devices, the powder properties (composition, particle size, shape, density) have to be
carefully adjusted [104]. It should be emphasised that, although adequate immune responses have
been observed in numerous preclinical and clinical studies, there are currently no ballistic injection
products authorised for human use. The main unsolved issues are the high cost, cutaneous adverse
reactions (e.g., erythema, petechiae, skin discoloration, oedema and skin flaking) and pain, that could
lead to reduced patient adherence [105,106].
Jet injection is another needle-free approach that delivers liquid vaccine formulations in a 2–500 µL
range using a highly pressured propulsion system connected to a needle-free syringe or nozzle [92,107].
The delivery of the vaccine can occur intradermally but also subcutaneously or even intramuscularly,
Vaccines 2020, 8, 304 14 of 28
forming a depot, depending on the applied velocity and overall design. Apart from a variation in the
depth of delivery, other safety-related issues are successfully circumvented by the fact that this method
now utilises prefilled disposable delivery units, thus avoiding contamination. If future research focuses
on achieving more cost-effective manufacturing, jet injectors may be a part of promising multi-platform
systems (e.g., coupled with nanoparticulate formulations) for driving further the cutaneous vaccination
approach [107,108].
The aforementioned physical devices, although efficient in antigen delivery into the skin, may lead
to some skin barrier damage, making them less suitable for mass vaccination under critical hygienic
conditions [108,109]. As a result, there has been an increasing interest in passive delivery strategies,
particularly nanocarriers, enabling antigen application to intact skin as well as improved antigen stability,
sustained antigen release and increased antigenicity by mimicking the size of microorganisms [108,110,111].
Until now, different nanoparticles have been studied for this purpose, including vesicular nanocarriers
(transfersomes, ethosomes, liposomes, niosomes, nanoemulsions) and solid nanoparticles (polymeric
nanoparticles, silica-based nanoparticles) [92,110]. However, although nanoparticles may lead to a
superior immune response compared to conventional intramuscular immunisation (particularly with
an appropriate adjuvant), progress towards clinical settings has been negligible, due to difficulties
in ensuring the accurate, reproducible and efficient delivery of antigen-loaded nanoparticles into the
epidermal and dermal tissue [109,111]. Interestingly, in recent years, vaccination via the follicular
route using nanoparticles, particularly non-flexible ones, has been recognised as a promising approach.
It offers a CD8+ T cell-biased immune response (due to a large number of perifollicular APCs) that
could be beneficial for the development of vaccines against intracellular pathogens, viruses and
cancers [112]. However, it is important to emphasise that research in this area is still at an experimental
stage, due to numerous factors affecting trans-follicular immunisation with nanoparticles, including
particle size, surface properties (charge and composition of surface layer) and hair cycling [109].
5. Controlled Antigen Release Delivery Systems for Single-Dose Immunisation
Since the early 1990s, there has been extensive research on controlled release delivery systems
for vaccine applications [113,114]. Prior to this, controlled delivery technologies were developed for
a sustained delivery of drug molecules and provided the basic understanding of controlled release
applications. This paved the way for delayed drug delivery technologies based on “smart” polymers,
such as biodegradable microparticles, solid implants or in-site gel-forming implants [115] and the
notion of developing biodegradable microparticles to accommodate prime-boost vaccine regimens
within a single-dose formulation [116]. Encapsulating the booster vaccine into polymer particles
should enable the pulsatile or continued release of the booster dose, that when combined with a free
priming vaccine, can mimic a prime-boost regimen within a single immunisation. This approach
would alleviate logistical challenges, the costs and the pressure on resources to deliver the booster
doses, leading to increased vaccination compliance and coverage globally. Vaccine encapsulation also
addresses the need for antigen sparing by improving immune responses through antigen shielding,
controlled antigen release and adjuvanting effect due to the particulate nature of the encapsulated
vaccine delivery system.
The biodegradable polymer of choice is the FDA-approved poly lactic-co-glycolic acid (PLGA),
which can be formulated into nano- and microparticles using a range of methods, the most common
being water-in-oil-in-water (W/O/W) double emulsion solvent evaporation. An advantage of using
polymer particles for vaccine delivery is that they can be adapted in size and/or structure to resemble a
pathogen or to achieve the targeted delivery to promote humoral and CMI responses [117,118]. Particle
size influences the immune response. For example, an efficient phagocytosis by macrophages may
induce a more rapid immune response, while larger particles avoid the direct uptake by APCs and
prolong antigen release [119–122]. Encapsulated antigens are protected from enzymatic degradation or
rapid elimination in vivo, further contributing to an enhanced immune response [117,118]. The tuneable
characteristics of the particulate vaccine delivery systems and the possibility for co-encapsulation
Vaccines 2020, 8, 304 15 of 28
or surface attachment of immunostimulatory agents play an important role in achieving the desired
immune responses or adjuvant effects [123,124]. Various administration routes showing pre-clinical
success have been reported for the oral, intranasal, parenteral and dermal delivery of antigens
encapsulated in PLGA particles. These vaccine candidates, formulated using the W/O/W method,
show great potential as a versatile vaccine delivery system and can achieve various immunologic
requirements such as boosting antibody titres and inducing a CMI response. Although PLGA-based
microparticles may no longer be a novel approach for vaccine delivery, there is a need for technological
innovation to achieve more efficient, cost-effective, preferably solvent-free manufacturing methods of
polymer-based controlled antigen-release delivery systems.
Progress of PLGA Polymer Vaccine Delivery Systems
The main method to achieve controlled antigen release has been the encapsulation into a polymer
matrix by the W/O/W method. To this day, it remains the classic method that has been used to produce a
wide array of particles with varying characteristics [125]. In general, for W/O/W, the primary emulsion
consists of the antigen in an aqueous buffer emulsified into an ‘oil’ phase containing the polymer of
choice in a selected solvent. This is followed by a secondary emulsification of the primary emulsion into
an aqueous solution containing stabilising surfactants. Lastly, during a solidification phase the particles
precipitate and harden as the solvent is evaporated. The manufacturing parameter of this method can
be modified at various steps to obtain particles with the desired physicochemical characteristics. PLGA
has been the most popular choice of biodegradable polymer and extensive research has demonstrated
the influence of the co-polymer ratio, polymer viscosity, molecular weight, volume ratios and end
caps on antigen release [116,126,127]. It is important to consider that it is not necessarily the PLGA
polymer itself, but the particulate nature of the delivery system that allows for its immune-enhancing
activity. The particulates are recognised as foreign material, triggering an immune response involving
phagocytosis, the production of cytokines and the further activation of T cells.
The potential of encapsulated vaccines was initially demonstrated using ovalbumin (OVA).
Superior IgG responses were detected in mice receiving subcutaneous immunisation of OVA
encapsulated in PLGA particles (10 µm) compared to OVA combined with Freund’s adjuvant [113].
Liu et al. demonstrated that more efficient cross-presentation was achieved with OVA adsorbed or
encapsulated into lipid-PLGA nanoparticles, exemplifying the potential to use integrated delivery
strategies [128]. Numerous studies have confirmed the influence of particle size on both release kinetics
and the resulting immune response [119,121]. Studies with smaller particles (0.3–7 µm) [129] and larger
particles (100–150 µm) [130] both reported superior IgG titres after intraperitoneal administration.
This highlights the difficulty of obtaining direct size and effect correlations for encapsulated vaccine
delivery systems. Depending on the antigen and the desired immune response, the optimal particle
size may differ greatly. Additionally, differences in the route of administration, animal models,
and encapsulation efficiencies should be considered.
Alternative polymer materials have also been explored. Microparticle formulation strategies based
on poly (D,L-lactic acid) (PLA) have been investigated in encapsulating various antigens including
rotavirus, tetanus toxoid and Vibrio cholerae [131]. PLA particles (2–8 µm) with encapsulated tetanus
toxoid, administered intramuscularly to Wistar rats, induced high antibody titres. A further increase
was observed when co-administered with Alhydrogel adjuvant [120,132]. The incorporation of poly
(ethylene glycol) (PEG) was investigated with Vibrio cholerae-loaded PLA/PEG microparticles (4–5 µm),
inducing high antibody titres as well as protection against a lethal challenge after oral administration
in CD-1 outbred mice [133].
The W/O/W method development includes combining PLGA with polysaccharides, or using
polysaccharides alone, to formulate antigen delivery systems. A combination of PLGA and sodium
alginate investigated for the intradermal delivery of encapsulated malaria peptides demonstrated
that particles of 1 µm induced a balanced Th1/Th2 response in BALB/c mice. In combination with
immunostimulatory peptides (Arg–Gly–Asp), a strong CMI response was measured compared to the
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antigen alone or encapsulated in PLGA only [134]. Cationic polymers, such as chitosan, have been
explored to formulate particles, however, these require emulsification with internal or external gelation
techniques. When combined into PLGA particles, chitosan takes on an adjuvant role due to its inherent
positive charge [135]. Novel functionalised dextrans have also been investigated in vaccine delivery
systems [136].
The co-delivery of the encapsulated antigen and an adjuvant to enhance antigen presentation
has been one of the focal points in the last decade, as characterisation methods have become
increasingly advanced. Microparticle formulations containing aluminium salts and TLR9 agonist CpG
oligonucleotides have shown that combining the antigen and adjuvant into a particulate delivery system
can result in robust immune responses for single-dose vaccines compared to multi-immunisation
schedules [124,132,137]. As mentioned above, other approaches have formulated the particles with
ligands such as mannose to achieve DC targeting [21,135].
Multi-platform systems such as the single-dose pandemic influenza vaccine of recombinant outer
membrane vesicles (rOMVs) encapsulated in PLGA demonstrated equivalent IgG titres to a prime and
boost regimen, and protected mice against a challenge with a lethal dose of H1N1, six months post the
initial vaccination. These microparticles (10–20 µm), manufactured using W/O/W, had a prolonged
antigen release over 30 days [138]. This work demonstrates that significant results can be achieved
when combining the classic W/O/W method with novel vaccine antigen technologies.
6. Advanced Vaccine Encapsulation Methods
The classic W/O/W emulsification method has a number of shortcomings that have impeded
the successful commercial development of an encapsulated antigen in polymer microparticles for
single-dose vaccines. Formulation issues and the lack of particle uniformity lead to uneven antigen
release profiles, including an initial burst (release of antigen upon injection) [139]. Considerable progress
has been made to develop encapsulation technologies that address the issues of antigen stability,
encapsulation efficiency, particle size and distribution and the suitable release profiles [140,141].
To encapsulate antigens, stability is critical and the encapsulation method needs to be optimised
for each vaccine. Antigen stability may be impaired due to mechanical and chemical stress induced
during emulsification steps. Novel encapsulation technologies that use milder processing methods
are likely to mitigate the mechanical stress and reduce solvent-surface interactions; one such
approach is coaxial electrospraying [142]. Furthermore, antigen stability can be achieved with the
co-encapsulation of stabilising additives such as hydrophilic PEG, surfactants, sugars, or protein serum
albumin [131,133,142]. The co-encapsulation of cationic excipients such as Eudragit E, poly(L-lysine)
and branched polyethylenimine has shown promising results for inactivated polio vaccine encapsulation
by W/O/W into PLGA microparticles [143].
The very adaptable process parameters of the W/O/W method have allowed the optimisation
of encapsulation processes to reach suitable encapsulation efficiencies. Nonetheless, the (double)
emulsification step means that the encapsulation process occurs at random. The spontaneous
emulsification (SE) solvent diffusion technique has been suggested as an improved method for
controlled protein encapsulation. With SE, a more homogenous distribution of the encapsulated
antigen is achieved, thus reducing the initial burst effect [139]. The SE method was validated by
encapsulating bovine serum albumin (BSA): the in vitro release kinetics demonstrated a pulsatile-release
of BSA and comparable antibody titres after a single-dose subcutaneous administration to BALB/c
mice [144]. Technologies such as microfluidics and spray-drying have demonstrated the feasibility of
more controlled encapsulation processes and may be critical in achieving the necessary encapsulation
efficiencies for large scale vaccine manufacturing.
It has been demonstrated that the W/O/W method can be adapted to produce particles of desired
size, however, it is quite difficult to achieve an extremely narrow size distribution (monodispersity).
The size variation is largely due to the emulsification step, during which the particles have different
droplet sizes, followed by variable precipitation rates during the solidification phase. The uniformity
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of particle size and distribution is also an important factor regarding the reproducibility and feasibility
to scale up. Sieving the particles after emulsification can result in more uniform particle preparations.
This is referred to as extrusion and achieved with Shirasu porous glass (SPG) beads [119,124,145].
Alternatively, encapsulation using novel microfluidic technologies may be a promising approach to
achieve both adaptable particle sizes and a narrow size distribution. There remains a concern of
translating laboratory-scale success to commercial-scale manufacture. Conventional emulsification
methods may be inflated to a large scale of more than hundreds of litres per hour, however, there are
numerous process parameters that need to be optimised individually [146]. This is an important aspect
to take into consideration when validating novel antigen encapsulation technologies.
There is an increasing interest in developing core-shell particles with hydrophilic cores to
maintain the microenvironment and therefore the conformation and biological integrity of the
antigen [147]. They can be formulated using W/O/W method, microfluidics, or by StampEd assembly
of polymer layers (SEAL), a recently reported microfabrication approach based on 3D printing [148].
Core:shell microparticles (25 µm) with an acceptable size distribution (span) of 1.4 were manufactured
using the W/O/W method combined with ionotropic gelation to form a sodium alginate-based
hydro-core (Figure 3a,b) (Lemoine et al., unpublished). Using fluorophore labelling and confocal
imaging, the core:shell structure of these particles was demonstrated and a variable distribution of the
alginate cores was observed. Comparatively, core:shell particles with different shell thicknesses were
manufactured by a microfluidics method. Using two microfluidic flow-focusing designs consecutively,
the core and shell size of the particles were modified independently to produce two different populations,
namely “thin-” and “thick-” shell particles. Both populations were highly monodispersed, with the
coefficient of variation less than 5% (Guyon et al., unpublished). Precise and identical size parameters
across a population of particles could contribute to a sharper burst release of the payload, as particles are
likely to exhibit the same behaviour if they are monodispersed. The identification of other significant
factors affecting the release is also more tractable when the size of a particle batch is controlled.
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capillaries assembled coaxially in “co-flow” type intersections or in microfluidic chips, often made 
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Figure 3. Core:shell microparticles prepared by two different manufacture methods. Confocal
images of (a) the microparticles by the water-in-oil-in-water (W/O/W) method, core: sodium alginate
75–200 kDa (NovaMatrix®), shell: PLGA–rhodamine (50:50 30 kDa); (b) the microparticles by the
W/O/W method, core: sodium alginate labelled with calcein, shell as in (a). Fluorescent microscopy
images (40 × magnification) of (c) the thin shell microparticles by the microfluidics method, core:
dextran-FITC 70 kDa, shell: PLGA resomer R502 (50:50 7–17 kDa); (d) thick shell microparticles by the
icrofluidics ethod (sa e para eters as in (c)).
7. pproaches to Encapsulation sing icrofluidics
icrofluidics involves the anipulation of fluid flo s at a icroscale, giving the fluids a la inar
behaviour, and is used in specific applications such as droplet icrofluidics. Thus, icrofluidics can
produce highly onodispersed droplets in a controlled and repeatable anner, a feature utilised in
drug delivery, and in particular for vaccine encapsulation.
In icrofluidics, droplets are generated by intersection designs, where two immiscible or partially
miscible phases are put into contact, and subsequently produce droplets by the combined actions of shear
stress, viscous forces, and interfacial tension. This process can be conducted in capillaries assembled
coaxially in “co-flow” type intersections or in microfluidic chips, often made with polydimethylsiloxane
(PDMS)—a silicon polymer poured onto a mould and hardened to form microfluidic chips—or with
glass, where the “T-junction” or “flo -focusing” designs are embedded. Multiple emulsions are formed
with the different fluids flowing through successive intersections, generating successive layers of the
multiple em lsion (see Figure 4). These template multiple emulsions, either produced by capillary
microfluidics [149,150], or chip microfluidics [151,152], are then converted into microcapsules.
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7.2. Towards Implementing icrofluidics for Vaccine Delivery Systems
Despite all the benefits of icrofluidics outlined here, no direct use of this technology in the
production of encapsulated vaccines for delayed delivery has been reported yet. Difficulties in setting
up adequate icrofluidics platfor and processes could be the ain reason. Indeed, icrofluidics
applications require both an accurate fluid flow controller, such as pressure pu ps and connected
reservoirs, or syringe pu ps, and an i aging syste , co posed of a icroscope, or a si ilar set of
lenses and light, and a high-speed ca era. These co ponents are not frequently found in biology
laboratories, and their setup and use also involves an engineering skill set.
oreover, the microfluidic element itself necessitates manufacturing that has not been upscaled for
mass production yet by the industry. Thus, capillary microfluidics systems are homemade, with many
challenges to face in the precise assembly, while microfluidic chips are in most cases produced by soft
lithography, involving clean room facilities and expertise.
The inability of icrofluidics syste s to achieve the yields of production needed by the drug
anufacturing industry is often mentioned as one of the major drawbacks of microfluidics approaches.
Vaccines 2020, 8, 304 20 of 28
Indeed, although microfluidic droplet generation rate can reach several kilohertz, the total volume
encapsulated is limited due to the inherent microscale aspect of the technology. However, parallelisation
approaches, where multiple droplet microfluidic processes are performed simultaneously with the
adequate designs, have been published and demonstrated more than acceptable throughputs [146,157,158].
Thus, Yadavali et al. reported a production rate of 277 g per hour of polycaprolactone microparticles
using a silicon and glass parallelised microfluidic device [158].
Finally, the cost of vaccination must be kept in consideration, in particular when developing
sophisticated technologies for vaccine formulation and delivery. The mobilisation of global funds
for vaccine development, led by the WHO and dedicated organisations such as the Gavi Alliance,
along with the scalability of methods and increasing the vaccine production capacity in the developing
countries which significantly reduces the cost per dose [159], can help accelerate access to vaccines
where they are most needed.
8. Conclusions
From the above considerations, it is evident that non-invasive vaccination systems are in
development as well as are advanced delivery systems that may prove to be an essential part
of promising multi-platform vaccine strategies. However, it has yet to be shown whether the presented
technologies may provide reliable and cost-effective approaches to vaccination, yielding more efficient
vaccines and improved patient compliance to immunisation programmes in both the developed and
the developing countries.
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